Author (Corporate) | European Medicines Agency |
---|---|
Series Title | Press Release |
Series Details | EMA/CHMP/257385/2012 (20.4.12) |
Publication Date | 20/04/2012 |
Content Type | News |
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), on 20 April 2012, recommended the granting of a marketing authorisation for Forxiga (dapagliflozin), a novel treatment for type 2 diabetes mellitus. |
|
Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/04/news_detail_001499.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp |
Related Links |
|
Subject Categories | Health |
Countries / Regions | Europe |